Resilient Extended Automatic Cell Therapies: enabling the body to make its own medicine.
ARPA-H’s Resilient Extended Automatic Cell Therapies (REACT) program seeks bioelectronic approaches to chronic disease care. It is organized around two proposed implantable devices: a “Living Pharmacy,” where engineered cells would produce and release prescribed therapies, and a “Living Sentinel,” where cells would detect disease-related biomarkers and relay information to a patient or care team. The program describes these devices as connecting with a software platform or app. Its stated aim is to support treatment delivery and disease monitoring for conditions that require ongoing management.
Be the first Cosign
Add it to your Products I use list. You can also share why you use it.
